AngioDynamics, Inc. (NASDAQ:ANGO) Sees Large Drop in Short Interest

AngioDynamics, Inc. (NASDAQ:ANGO) was the target of a large decrease in short interest in February. As of February 13th, there was short interest totaling 1,699,336 shares, a decrease of 17.6% from the January 29th total of 2,062,441 shares. Based on an average daily volume of 449,317 shares, the short-interest ratio is presently 3.8 days. Currently, 4.4% of the shares of the stock are short sold. Currently, 4.4% of the shares of the stock are short sold. Based on an average daily volume of 449,317 shares, the short-interest ratio is presently 3.8 days.

AngioDynamics Stock Down 0.5%

ANGO opened at $10.99 on Thursday. AngioDynamics has a twelve month low of $8.27 and a twelve month high of $13.99. The company has a fifty day moving average of $11.09 and a 200-day moving average of $11.44. The stock has a market cap of $453.01 million, a PE ratio of -16.40 and a beta of 0.48.

Institutional Investors Weigh In On AngioDynamics

Several large investors have recently added to or reduced their stakes in the business. Mercer Global Advisors Inc. ADV increased its holdings in AngioDynamics by 38.1% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 14,604 shares of the medical instruments supplier’s stock worth $188,000 after purchasing an additional 4,030 shares in the last quarter. XTX Topco Ltd increased its stake in shares of AngioDynamics by 69.6% in the 4th quarter. XTX Topco Ltd now owns 40,811 shares of the medical instruments supplier’s stock valued at $524,000 after acquiring an additional 16,742 shares in the last quarter. Quadrature Capital Ltd acquired a new position in shares of AngioDynamics during the 4th quarter valued at $463,000. Manatuck Hill Partners LLC boosted its stake in AngioDynamics by 6.3% during the fourth quarter. Manatuck Hill Partners LLC now owns 425,000 shares of the medical instruments supplier’s stock worth $5,457,000 after acquiring an additional 25,000 shares in the last quarter. Finally, Engineers Gate Manager LP bought a new position in AngioDynamics during the fourth quarter worth $204,000. Institutional investors and hedge funds own 89.43% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a report on Wednesday, January 21st. Zacks Research raised shares of AngioDynamics from a “hold” rating to a “strong-buy” rating in a report on Friday, January 9th. Finally, Wall Street Zen cut shares of AngioDynamics from a “buy” rating to a “hold” rating in a research report on Sunday, December 21st. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, AngioDynamics has an average rating of “Moderate Buy” and a consensus target price of $19.33.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.